| Product Name | 3,7,4'-Trihydroxy-5-methoxy-8-prenylflavanone, (2R,3R)- |
|---|---|
| CAS | 204935-85-3 |
| Formula | C21H22O6 |
| MW | 370.40 |
| Appearance | |
| Melting point | 194-198 °C |
| Boiling point | 631.0±55.0 °C | Condition: Press: 760 Torr |
| PKa | 7.80±0.60 | Condition: Most Acidic Temp: 25 °C |
WKQ-0001635
中文名稱：(2R,3R)-3,7,4'-三羥基-5-甲氧基-8-異戊烯基二氫黃酮
中文別名：4'-三羥基-5-甲氧基-8-異戊烯基二氫黃酮；(2R,3R)-3,7,4-三羥基-5-甲氧基-8-異戊烯基二氫黃酮
英文名稱：3,7,4'-Trihydroxy-5-methoxy-8-prenylflavanone, (2R,3R)-
英文別名：4H-1-Benzopyran-4-one, 2,3-dihydro-3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methyl-2-butenyl)-, (2R,3R)- (9CI);4H-1-Benzopyran-4-one, 2,3-dihydro-3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methyl-2-butenyl)-, (2R-trans)-;(2R,3R)-2,3-Dihydro-3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one;(2R)-3β,7,4'-Trihydroxy-5-methoxy-8-(γ,γ-dimethylallyl)flavanone;(2R)-3β,7,4'-Trihydroxy-5-methoxy-8-prenylflavanone;(2S)-3,7,4'-Trihydroxy-5-methoxy-8-(γ,γ-dimethylallyl)flavanone;3,7,4'-Trihydroxy-5-methoxy-8-prenylflavanone;3β,7,4'-Trihydroxy-5-methoxy-8-[3,3-dimethylallyl]flavanone;
分子式：C21H22O6
分子量：370.40
CAS號(hào)：204935-85-3
純度：HPLC≥98%
熔點(diǎn)：194-198 °C
沸點(diǎn)：631.0±55.0 °C | Condition: Press: 760 Torr
密度：1.315±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數(shù)：7.80±0.60 | Condition: Most Acidic Temp: 25 °C
儲(chǔ)存條件：-20℃，干燥、避光、密封
規(guī)格：5mg10mg20mg50mg100mg500mg1g2g等應(yīng)客戶需求包裝
供應(yīng)單位：四川省維克奇生物科技有限公司
供應(yīng)電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產(chǎn)中藥類標(biāo)準(zhǔn)品和天然植物有效單體，主打中藥對(duì)照品/標(biāo)準(zhǔn)品/天然植物有效單體，化學(xué)合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲(chóng)草系列等，敬請(qǐng)關(guān)注！ 新批次有現(xiàn)貨，歡迎咨詢。
| Integrated metabolomics and network pharmacology strategy for ascertaining the quality marker of flavonoids for Sophora flavescens | ||
| Source:SCI：JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | Author:Lei Chen | Notes：影響因子：3.209 |
| Reference description | ||
Reference standards were used in this study, twenty-eight of them were self-made by our laboratory in the early stage [[16], [17], [18]], including 3′-hydroxy-daidzein, calycosin, trifolirhizin, genistein, maackiain, sophoraflavescenol, noranhydroicaritin, shandougenines B, kushenol C, leachianone G, liquiritigenin, 8-(3-hydroxymethyl-2-butenyl)-5,7,2′,4′-tetrahydroxyflavanone, 2′-hydroxy-isoxanthohumol, (2R)-3β,7,4′-trihydroxy-5-methoxy-8-prenylflavanone, (2R)-3α,7,4′-trihydroxy-5-methoxy-8-prenylflavanone, 4H-1-benzopyran-4-one,2-(4-hydroxyphenyl)-3,7-dihydroxy-5-methoxy-8-[5-methyl-2-(1-methylethenyl)-4-hexenyl], isoxanthohumol, kurarinol, kushenol N, kurarinone, isokurarinone, kushenol U, 2′-methoxykurarinone, norkurarinone, kushenol A, kushenol L, kuraridin, xanthohumol and biochanin A, kushenol B and kushenol M were purchased from Sichuan Weikeqi Biological Technology Co., Ltd (Sichuan China) and Wuhan Tianzhi Biotechnology Co., Ltd. (Wuhan, China), kushenol E and kushenol X were donated by Dr. YY Jiang from Beijing University of Chinese Medicine. The purity of the above standards is greater than 98 %. | ||
